In which clinical situations is the use of an Acapella (oscillatory positive‑expiratory pressure) device indicated?

When is the Use of an Acapella Indicated?

The Acapella device (oscillatory positive expiratory pressure therapy) is indicated for patients with bronchiectasis who produce sputum daily or most days, patients with COPD who have regular sputum production, and post-operative cardiac or thoracic surgery patients to facilitate airway clearance and prevent pulmonary complications.

Primary Indications

Bronchiectasis with Daily Sputum Production

The 2019 British Thoracic Society guideline 1 discusses the Acapella as part of airway clearance techniques for bronchiectasis, though the evidence base is limited. A single crossover study showed the Acapella cleared 0.7 mL more sputum than inspiratory muscle training, though this difference is clinically marginal 1. The 2018 CHEST expert panel 2 found only very low-quality evidence for oscillatory PEP devices in non-CF bronchiectasis, with one small study of 20 patients showing nonsignificant reduction in exacerbations when using Acapella versus no chest physiotherapy.

Despite limited guideline-level evidence, the most recent high-quality research strongly supports use in this population. A 2023 randomized controlled trial 3 demonstrated that regular Acapella use in COPD patients with daily sputum production improved:

• Cough-related quality of life (Leicester Cough Questionnaire improvement of 1.03 points, p=0.03)
• Fatigue scores (FACIT improvement of 4.68 points, p<0.001)
• Generic quality of life (EQ-5D improvement of 4.00 points, p=0.04)
• Objective cough frequency (reduction of 60 coughs per 24 hours, p<0.001)

COPD with Regular Sputum Production

For COPD patients who produce sputum every day or most days, the Acapella device should be prescribed for regular use (typically 3 times daily). The 2023 O-COPD trial 3 provides the strongest evidence for this indication, showing meaningful improvements in both subjective and objective outcomes over 3 months of use.

Post-Operative Cardiac Surgery

Acapella therapy should be initiated 10-12 hours after tracheal extubation in post-CABG patients and continued 3 times daily for the first 3-6 days post-operatively. A 2022 randomized trial 4 showed that adding Acapella to conventional chest physiotherapy in CABG patients resulted in:

• Significantly greater improvements in FVC (0.44 L difference), FEV1 (0.43 L difference), and PEFR (0.86 L/s difference) by post-operative day 6
• Greater sputum expectoration (2.71 mL more than control)

A 2023 Russian study 5 in cardiac surgery patients demonstrated that 3-day oscillatory PEP therapy sessions led to:

• 3-fold increase in productive cough
• 46.9% increase in maximum inspiratory capacity
• 7-fold decrease in radiological lung changes (p<0.001)
• 8.6-fold decrease in patients with respiratory insufficiency (SpO2≤92%)

Post-Operative Thoracic Surgery

For lung cancer patients undergoing VATS lobectomy, perioperative Acapella training should be implemented. A 2018 Chinese study 6 showed that oscillatory PEP training in VATS patients reduced:

• Postoperative pulmonary complications (2.9% vs 20.6%, p=0.03)
• Atelectasis incidence (0% vs 14.7%, p=0.03)
• Hospital stay duration (5.09 vs 7.68 days, p=0.01)
• Drug costs (¥4,413 vs ¥6,490, p=0.01)

Contraindications and Precautions

Before prescribing Acapella therapy, ensure patients do NOT have:

• Active pneumothorax
• Active hemothorax or ongoing bleeding
• Inability to maintain adequate gas exchange on low-flow oxygen
• Severe cardiac insufficiency (inotropic index >10)
• Shock of any etiology
• Acute cerebrovascular accident
• Inability to follow instructions or maintain productive contact

Practical Implementation

Typical prescription:

• Frequency: 3 times daily
• Duration: 10-15 minutes per session
• Technique: Sitting position with huffing included
• Device setting: Adjust resistance based on patient tolerance (Acapella devices come in different resistance levels)

Evidence Quality Considerations

A critical caveat: The guideline-level evidence 2, 1 rates the quality of evidence for Acapella in bronchiectasis as very low, based on small studies with high risk of bias. However, the most recent 2023 RCT 3 provides substantially stronger evidence with objective outcome measures including 24-hour cough monitoring, representing a significant advancement beyond what the older guidelines captured.

The Cochrane review 7 from 2017 concluded that oscillatory PEP therapy has similar effects to other airway clearance techniques, with low overall quality of evidence. This suggests that while Acapella may not be superior to other techniques, it represents a valid option that patients may find more convenient or preferable for home use.

Patient Selection Algorithm

Prescribe Acapella when:

1. Patient has bronchiectasis OR COPD with daily/most days sputum production
2. Patient is post-operative cardiac or thoracic surgery (days 1-6)
3. Patient can sit upright and follow instructions
4. No contraindications present

Consider alternative techniques when:

• Patient prefers other methods (patient preference matters for adherence)
• Severe GORD symptoms (though no direct evidence of harm, postural drainage may be more problematic)
• Cost is prohibitive (device required for home use)